KIT and melanoma: Immune checkpoint inhibitors, the standard treatment for melanoma therapy, remain indicated for KIT-mutant cases and have demonstrated efficacy in some patients, particularly in the metastatic setting and in TKI-resistant mutations [54,55,56,57,58,59,60].